A prior study compared retention rates following TNFα inhibitor treatment (etanercept, infliximab, and adalimumab) in rheumatoid arthritis, psoriatic arthritis and AS, and found the cumulative survival to favor AS patients.25 The gene discussed is TNF; the disease is psoriatic arthritis.